Related references
Note: Only part of the references are listed.The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Achieving systemic delivery of oncolytic viruses
Claudia Hill et al.
EXPERT OPINION ON DRUG DELIVERY (2019)
Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy
Weizhou Hou et al.
CANCER CELL (2016)
Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery
Luis Alfonso Rojas et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus
Rachel Myers et al.
MOLECULAR THERAPY (2016)
Single-particle characterization of oncolytic vaccinia virus by flow virometry
Vera A. Tang et al.
VACCINE (2016)
Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies
Juan J. Rojas et al.
CELL REPORTS (2016)
Cholesterol Modified Self-Assemblies and Their Application to Nanomedicine
Francesca Ercole et al.
BIOMACROMOLECULES (2015)
Increasing the density of nanomedicines improves their ultrasound-mediated delivery to tumours
Steven Mo et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Se Hoon Park et al.
MOLECULAR THERAPY (2015)
Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques
Laura Evgin et al.
MOLECULAR THERAPY (2015)
Sorting of small infectious virus particles by flow virometry reveals distinct infectivity profiles
Raphael Gaudin et al.
NATURE COMMUNICATIONS (2015)
Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus
Naba Elsaid et al.
EXPERIMENTAL EYE RESEARCH (2014)
Nanoparticle-based flow virometry for the analysis of individual virions
Anush Arakelyan et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound
Robert Carlisle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Jeong Heo et al.
NATURE MEDICINE (2013)
Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer
Nieola K. Green et al.
NANOMEDICINE (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
Poly(ethylene glycol)-Lipid-Conjugated Antibodies Enhance Dendritic Cell Phagocytosis of Apoptotic Cancer Cells
Urara Tomita et al.
PHARMACEUTICALS (2012)
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma
Tae-Ho Hwang et al.
MOLECULAR THERAPY (2011)
PEGylated Adenoviruses: From Mice to Monkeys
Piyanuch Wonganan et al.
VIRUSES-BASEL (2010)
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1
Robert C. Carlisle et al.
BLOOD (2009)
Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer
Nicola K. Green et al.
JOURNAL OF GENE MEDICINE (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor
Joanne Morrison et al.
MOLECULAR THERAPY (2008)
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Roberto Cattaneo et al.
NATURE REVIEWS MICROBIOLOGY (2008)
Specific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles
Stephane Paul et al.
VIRAL IMMUNOLOGY (2007)
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
Steve H. Thorne et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy
Kerry D. Fisher et al.
JOURNAL OF DRUG TARGETING (2007)
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF
J. H. Kim et al.
MOLECULAR THERAPY (2006)
Real-time virus trapping and fluorescent imaging in microfluidic devices
D Akin et al.
NANO LETTERS (2004)
Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus
NK Green et al.
GENE THERAPY (2004)
MUC1, the renaissance molecule
SJ Gendler
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2001)
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
KD Fisher et al.
GENE THERAPY (2001)
Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer
SM Scholl et al.
JOURNAL OF IMMUNOTHERAPY (2000)
Share Paper
